Reportable Segment Information (Tables)

12 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Segment Revenue, Operating (Loss) Income and Depreciation and Amortization

Segment revenue, operating (loss) income, and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2022			2021			2020
Revenue:
Medical Device	$	72,389		$	78,253		$	71,401
In Vitro Diagnostics		27,562			26,883			23,463
Total revenue	$	99,951		$	105,136		$	94,864
Operating (loss) income:
Medical Device	$	(22,923	)	$	4,683		$	(3,246	)
In Vitro Diagnostics		13,073			13,770			11,771
Total segment operating (loss) income		(9,850	)		18,453			8,525
Corporate		(12,247	)		(11,750	)		(9,776	)
Total operating (loss) income	$	(22,097	)	$	6,703		$	(1,251	)
Depreciation and amortization:
Medical Device	$	8,368		$	7,224		$	6,223
In Vitro Diagnostics		355			395			483
Corporate		419			398			557
Total depreciation and amortization	$	9,142		$	8,017		$	7,263

Geographic Revenue and Long-lived Assets

Revenue by geographic region was as follows:

	Fiscal Year
	2022			2021			2020
Domestic		74	%		79	%		78	%
Foreign		26	%		21	%		22	%

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2022		2021
U.S.	$	24,788	$	25,920
Ireland		30,505		41,224